Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.51 USD | +2.36% | +4.49% | -25.77% |
Mar. 27 | MiMedx Group Says FDA Affirms Axiofill Falls Short of Regulatory Standards for Tissue-Based Products | MT |
Mar. 27 | MiMedx Says FDA Still Won't Budge on Axiofill Designation, Files Lawsuit | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.77% | 935M | |
-19.12% | 129M | |
+10.84% | 61.54M | |
-15.49% | 60.24M | |
+13.60% | 58.57M | |
-2.40% | 50.41M |
- Stock Market
- Equities
- MDXG Stock
- News MiMedx Group, Inc.
- MiMedx : Earnings Flash (MDXG) MIMEDX GROUP Reports Q2 Revenue $68.2M, vs. Street Est of $58.8M